The present invention relates to methods of treating diseases or disorders affecting the eye or optic nerve characterised by elevated .beta.-amyloid levels or .beta.-amyloid deposits, particularly age related macular degeneration and glaucoma type diseases and .beta.-amyloid dependent cataract formation, with antigen binding proteins that bind .beta.-amyloid peptide and in particular human .beta.-amyloid peptide.
申请公布号
CA2700481(A1)
申请公布日期
2009.04.02
申请号
CA20082700481
申请日期
2008.09.23
申请人
GLAXO GROUP LIMITED
发明人
BURBIDGE, STEPHEN ANTHONY;CATCHPOLE, IAN RICHARD;ELLIS, JONATHAN HENRY;FORD, SUSANNAH KAREN;GERMASCHEWSKI, VOLKER;KUMAR, UMESH;PHILPOTT, KAREN LOUISE;SODEN, PETER ERNEST;GOUGH, GERALD WAYNE
